Epidemiologie - France Portal | Health Databases

Home

Catalogue

Catalogue
ARCHIVES

Covid-19

Resources

Lexicon
Legal notices

Useful links

General links
Covid-19 links

Login in to your account

Email address Password

You do not have an account yet ? Sign up !

You have forgotten your password ?

Portail Epidémiologique

ITMO public health Aviesan

Aviesan

Archives

Search with one or more keywords

All records French records only English records only

This page gives you access to all the studies carried out by French researchers, identified on Covid-19.

To view other resources related to Covid-19, click here.

xml

Export to XML

Please choose the format :

pdf

Export to PDF

Which version do you want to export ?

Download full content

Download light content

csv

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection

ARCHIVES : 309 forms

Sorting of results :

PRESAGE - Observationnal study on Postmenopausal woman

Head : Hébuterne Xavier, Eli Lilly France

Version 1

211

Last update : 01/01/2018

ARCHIVE

PRESAGE - Observationnal study on Postmenopausal woman

Head : Hébuterne Xavier, Eli Lilly France

Main objective

Primary objective: estimate the percentage of osteoporotic patients among postmenopausal patients with a mineral bone density measurement for diagnosis purposes and who can benefit from therapeutic recommendations according to French recommendations.
Secondary objectives: factors associated with osteoporosis, characteristics and care for patients

Inclusion criteria

Postmenopausal woman,
- Patient not treated for osteoporosis for at least one year (HRT, raloxifene, bisphosphonate, teriparatide, strontium ranelate),
- Patient coming for a bone densitometry for diagnosis purposes,
- Patient able to benefit from a therapeutic recommendation for the treatment of osteoporosis (osteopenic or osteoporotic patient with risk factors of fractures).

Last update : 01/01/2018

ARCHIMED VILLE - Prevention of venous thromboembolic events with Arixtra 2.5mg for medical ill patients in general practice

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Version 1

212

Last update : 01/01/2020

ARCHIVE

ARCHIMED VILLE - Prevention of venous thromboembolic events with Arixtra 2.5mg for medical ill patients in general practice

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Main objective

Evaluate the average duration of treatment via ARIXTRA® 2.5 mg with thromboprophylaxis in ambulatory general practice

Inclusion criteria

Patient of at least 18 years of age,
-bedridden or with reduced mobility,
-for whom a treatment via ARIXTRA® 2.5 mg is initiated with thromboprophylaxis.

Last update : 01/01/2020

Episurvey Hepatite B - A cross-sectional, multicentre, epidemiological study of the drug management in hepatitis B

Head : Bregman Bruno, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Version 2

213

Last update : 09/05/2017

ARCHIVE

Episurvey Hepatite B - A cross-sectional, multicentre, epidemiological study of the drug management in hepatitis B

Head : Bregman Bruno, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Main objective

Describe the drug management of patients having chronic hepatitis B, in France, in 2006.

Inclusion criteria

M/F >=18 years, infected by the hepatitis B virus for at least 6 months, seen in outpatient clinic visit at expert centers for caring of hepatitis (Hepatitis Referenced University Hospitals, General Hospital Centres, community-based hepato-gastroenterologists) between 1 Jan. and 31 March 2006.

Last update : 09/05/2017

EMPATHIE - Enfants - Parents - Trouble déficit de l’attention avec Hyperactivité : Impact et Evaluation

Head : Ponthieux Anne

Version 1

214

Last update : 12/01/2018

ARCHIVE

EMPATHIE - Enfants - Parents - Trouble déficit de l’attention avec Hyperactivité : Impact et Evaluation

Head : Ponthieux Anne

Main objective

Study of the impact of the Attention-Deficit Hyperactivity Disorder (ADHD) on the parents/tutors of afflicted school children.
The study also strives to evaluate the impact of the ADHD on the siblings of the children afflicted and likewise of the impact of the disease on the school environment, thanks to the evidence provided by parents/tutors.

Inclusion criteria

Inclusion criteria for parents/tutors:
- Parents (father, mother or tutors) of a child aged 6 to 18 years suffering from ADHD
- Parents (father, mother, or tutors) accompanying their ADHD children for a routine consultation during the observation period,
- Parent (father, mother or tutor) of an child whether or not treated for his/her ADHD.

Inclusion criteria for siblings:
- Brother or sister without ADHD of a child corresponding to the aforementioned criteria,
- Brother or sister at least 9 years old and living with the ADHD child.

Non-inclusion criteria :
- ADHD child with important co-morbidity that could influence assessment of ADHD impact on psycho-socio-economic value,
- Patients sibling / parents with important co-morbidity that could influence the evaluation of their experience (i.e. at the level of the socio-psycho-economic impact),
- Parents unable to complete a self-questionnaire,
- Parents who participated to the feasability study (interviews)

Last update : 12/01/2018

- 2008 Health and nutrition Barometer

Head : Escalon Hélène, Département Enquêtes et Analyses Statistiques
Beck François, Responsable du département Enquêtes et Analyses Statistiques

Version 1

215

Last update : 01/01/2018

ARCHIVE

- 2008 Health and nutrition Barometer

Head : Escalon Hélène, Département Enquêtes et Analyses Statistiques
Beck François, Responsable du département Enquêtes et Analyses Statistiques

Main objective

Evaluate diet and physical activity behaviors, attitudes and knowledge of french people

Inclusion criteria

Querying people in households:
-equipped with a landline telephone (white, orange or red list)
-equipped solely with a mobile telephone
- and fully unbundled

Last update : 01/01/2018

KARU-PROSTATE - Case-Control Study on the Impact of Chlordecone Exposure and Risk of Prostate Cancer in the West Indies

Head : Multigner Luc , U1085 Research Institute of Health, Environment and Work

Version 1

216

Last update : 09/05/2017

ARCHIVE

KARU-PROSTATE - Case-Control Study on the Impact of Chlordecone Exposure and Risk of Prostate Cancer in the West Indies

Head : Multigner Luc , U1085 Research Institute of Health, Environment and Work

Main objective

To identify the environmental and genetic risk factors of prostate cancer and to assess the impact of chlordecone exposure in the onset of the disease.

Inclusion criteria

– Male
– Adult
– Caribbean native (Guadeloupe, Martinique, Haiti, Dominica)

Last update : 09/05/2017

Previous
1
...
30
31
32
33
34
35
36
37
38
39
40
41
42
...
52
Next

Please wait...

ABOUT

Help about your workspace

CATALOG

RESOURCES

USEFUL LINKS

This site complies with the HONcode standard for trustworthy health information:
verify here.

8 rue de la Croix Jarry

75013 Paris

Phone : +33 1 44 23 67 47

portail-epidemiologie@inserm.fr

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

XXX

View Edit Create here